Few London-listed companies command a medicine cabinet quite like Haleon plc. The maker of Sensodyne toothpaste, Panadol painkillers and Centrum vitamins arrived on the LSE in July 2022 as a demerger from GSK, instantly joining the FTSE 100. Nearly four years on, and now free of both former parents, the group is being watched as a test of whether steady, brand-led 'everyday health' can deliver dependable growth through uncertain consumer cycles.
The Quick Version
- Haleon reported £11,030m of revenue for FY2025 with 3.0% organic growth and a 22.9% adjusted operating margin, though reported revenue fell 1.8% partly on currency.
- Oral Health, led by Sensodyne and parodontax, is the standout category, growing 7.9% organically in FY2025 and 8.3% in Q1 2026.
- Both former parents have exited: GSK sold its residual stake in May 2024 and Pfizer completed its exit in March 2025, leaving Haleon fully independent.
- The group is returning cash through a rising dividend (up 7.6% for FY2025) and a £500m buyback allocation for 2026, alongside deleveraging.
- Key uncertainties include weak cold and flu seasons, US market softness, currency headwinds and net debt at 2.6x adjusted EBITDA.
What Haleon Actually Sells
Haleon makes and sells branded, largely over-the-counter products for everyday health — oral care, pain relief, vitamins and supplements, respiratory and digestive health, and therapeutic skin health. This is FMCG with a healthcare tilt, not a clinical-stage drug developer. Its 'power brands' include Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren, alongside a wider stable of local labels. The company employed around 24,000 people as of 2024, listed on the LSE (FTSE 100) under HLN, with a secondary NYSE listing.
Now Fully Independent
GSK sold its residual holding in May 2024, and Pfizer completed disposal of its remaining stake — reported at around 7.3% for roughly £2.5bn — in March 2025. The overhang of large, gradually-selling parent shareholders had been a recurring theme in commentary on the stock; its removal means the register is now more conventionally institutional.
The Numbers
For the twelve months ended 31 December 2025, revenue was £11,030m. Organic revenue growth was 3.0%, while reported revenue fell 1.8% — a gap reflecting currency movements and disposals. Adjusted operating profit was £2,526m (22.9% margin), and adjusted diluted EPS rose 5.0% to 18.8p. Free cash flow was £1,913m. Net debt sits at 2.6 times adjusted EBITDA. Shareholder returns totalled around £1.1bn in FY2025, the full-year dividend rose 7.6%, and £500m was allocated to buybacks for 2026.
Q1 2026 (to 31 March 2026) showed organic revenue growth of 2.2% and reported revenue of £2,857m, up 0.1%. A weak cold and flu season took roughly 130 basis points off the quarter's growth. Management reaffirmed full-year 2026 guidance of 3-5% organic growth and high-single-digit adjusted operating profit growth at constant currency.
Where the Growth Actually Comes From
Oral Health is clearly the engine — Sensodyne and parodontax drove 7.9% organic growth in FY2025 and 8.3% in Q1 2026. Other categories are more mixed: Pain Relief was down 0.3% organically in Q1 2026, Respiratory Health down 3.4% (illustrating seasonality — a soft cold and flu season directly hit Theraflu and Otrivin), Digestive Health down 0.4%, and Therapeutic Skin Health up 3.0%. Regionally, FY2025 growth was led by APAC (5.2%) and EMEA & LatAm (4.7%), while North America edged down 0.4%.
Why 'Resilient' Doesn't Mean Risk-Free
The broad case for consumer healthcare rests on structural demand: ageing populations, rising health awareness, self-care growth and emerging-market income growth. These are habitual purchases that tend to hold up better than discretionary spending. But the early-2026 softness across several categories, sensitivity to cold and flu seasons, and the ongoing North American challenge show 'resilient' doesn't mean immune to demand cycles or currency swings.
Competitive Landscape
Haleon's closest listed peers include Kenvue (former J&J consumer health, Tylenol/Listerine) and Reckitt (Nurofen, Strepsils), alongside Bayer's consumer health division, Procter & Gamble in oral/personal care, and Nestlé Health Science in nutrition, plus growing private-label competition. Haleon's leadership in oral health is a genuine point of strength; the softness in pain relief, respiratory and digestive health shows it's not immune to demand cycles.
Risks Worth Weighing
Seasonality is structural — a weak cold and flu season can knock a meaningful slice off quarterly respiratory growth. Currency is a persistent swing factor. Consumer trade-down toward private label is an ever-present FMCG threat. Category-specific legal and regulatory risks exist around certain OTC ingredients. Net debt, while falling, remains meaningful at 2.6x adjusted EBITDA.
What to Watch Next
Continued momentum in Oral Health, a recovery in North American volumes, further margin expansion, and additional shareholder returns should cash generation stay strong. A normal or strong cold and flu season would flatter the respiratory category after a soft comparative. Delivery against, or an upgrade to, 2026 guidance.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...